Septerna Q2 revenue beats analyst estimates, driven by Novo Nordisk partnership
SEPN•Revenue and spending drivers
- Collaboration revenue - Q2 revenue increase driven by the Novo Nordisk partnership, including amortization of upfront payment, milestone achievement and research services
- R&D spending - Higher research and development expenses reflect ongoing investment in the clinical pipeline
Outlook for SEP-479 and SEP-631
- Septerna expects to report SEP-479 Phase 1 SAD/MAD data in Q1 2027
- The company anticipates its cash position will fund operations at least into 2029
- Septerna is evaluating development strategies for SEP-631 in mast cell-driven diseases
Key quarterly figures and analyst view
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Beat | $26.75 million | $17.88 million (8 analysts) |
| Q2 Net Loss | $13.03 million | ||
| Q2 Loss From Operations | $16.84 million |
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell". The average consensus recommendation for the biotechnology & medical research peer group is "buy". Wall Street's median 12-month price target for Septerna, Inc. is $44.00, about 13.3% above its August 7 closing price of $38.83.
Q2 revenue rises on Novo Nordisk partnership
Related News
Upwork Q2 net income falls 22% on lower client, GSV base; issues soft Q3 revenue forecast
UPWK•
Ceribell Q2 FY26 net loss widens 41% to $19.27 million; revenue rises 33% to $28.1 million
CBLL•
